Lilly partners with Hims & Hers on obesity drug sales
Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
Inflammation-focused Rezera sets terms for IPO
Rezera, formerly known as NodThera, has announced the terms of its planned IPO, hoping to raise upwards of $200m for its NLRP3 inhibitor pipeline.
Moderna, Oxford Uni Ebola jabs backed for pivotal testing
Two more Ebola vaccines are set to be added to a trial in the Democratic Republic of the Congo (DRC), currently battling its largest-ever outbreak.
UK pilots shorter NICE appraisal for new medicines
NICE and NHS England are piloting a shorter initial assessment process for promising new medicines, aiming to slash times from 12 to six months.
J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod
The FDA has approved Johnson & Johnson's Rybrevant Faspro for head and neck cancer, extending the franchise beyond lung cancer for the first time.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
PMi Awards 2026: innovation, connection and a changing indus...
One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.
LEAP HR: Life Sciences Europe
Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences
Rational Based Drug Design Summit Europe
Driving Safer, Faster & More Efficient Discovery Across Europe
Evolution Summit 2027 to Convene Senior Clinical Development...
Westlake Village, CA: Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives
ISMAI 2026: Florence to host international symposium on the ...
On 3 and 4 December, in the CTO Auditorium of Careggi University Hospital, clinicians, scientists and international experts will discuss clinical judgement, patient safety and professional acco